BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blum K, Whitney D, Fried L, Febo M, Waite RL, Braverman ER, Dushaj K, Li M, Giordano J, Demetrovics Z, Badgaiyan RD. Hypothesizing that a Pro-Dopaminergic Regulator (KB220z Liquid Variant) can Induce "Dopamine Homeostasis" and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence. Clin Med Rev Case Rep 2016;3:125. [PMID: 29034323 DOI: 10.23937/2378-3656/1410125] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Madigan MA, Gupta A, Bowirrat A, Baron D, Badgaiyan RD, Elman I, Dennen CA, Braverman ER, Gold MS, Blum K. Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence? Int J Environ Res Public Health 2022;19:6395. [PMID: 35681980 DOI: 10.3390/ijerph19116395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Downs BW, Kushner S, Bagchi M, Blum K, Badgaiyan RD, Chakraborty S, Bagchi D. Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise. CPSP 2021;10:123-137. [DOI: 10.2174/2211556010666210122145526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Blum K, Khalsa J, Cadet JL, Baron D, Bowirrat A, Boyett B, Lott L, Brewer R, Gondré-Lewis M, Bunt G, Kazmi S, Gold MS. Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis. Front Psychiatry 2021;12:623403. [PMID: 33868044 DOI: 10.3389/fpsyt.2021.623403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Brewer R, Blum K, Bowirrat A, Modestino EJ, Baron D, Badgaiyan RD, Moran M, Boyett B, Gold MS. Transmodulation of Dopaminergic Signaling to Mitigate Hypodopminergia and Pharmaceutical Opioid-induced Hyperalgesia. CPSP 2020;9:164-184. [DOI: 10.2174/2211556009999200628093231] [Reference Citation Analysis]
5 Gold MS, Baron D, Bowirrat A, Blum K. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome? J Neurol Sci 2020;418:117137. [PMID: 32957037 DOI: 10.1016/j.jns.2020.117137] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
6 Blum K, Lott L, Baron D, Smith DE, Badgaiyan RD, Gold MS. Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual. J Syst Integr Neurosci 2020;7. [PMID: 32934823 DOI: 10.15761/JSIN.1000229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
7 Blum K, Gold M, Modestino EJ, Baron D, Boyett B, Siwicki D, Lott L, Podesta A, Roy AK, Hauser M, Downs BW, Badgaiyan RD. Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)? J Syst Integr Neurosci 2018;4. [PMID: 31750006 DOI: 10.15761/JSIN.1000196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kenneth B, Edward MJ, Marjorie GLC, David B, Bruce S, Panayotis TK, William DB, Davis S, Lisa L, Eric BR, Mark M, David M, Lyle F, Rajendra BD. Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated). CPQ Neurol Psychol 2018;1:https. [PMID: 30957097] [Reference Citation Analysis]